The ABCD of GOLD made clear

European Respiratory Journal

Volumn 42, Issue 5, 2013, Pages 1163-1165

  Calverley, Peter M A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; DISEASE EXACERBATION; EDITORIAL; HUMAN; LUNG FUNCTION; MASS SCREENING; MEDICAL SOCIETY; MORTALITY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROGNOSIS; SYMPTOMATOLOGY;

FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE;

EID: 84887311230     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00117413     Document Type: Editorial

References (22)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
2. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368: 351-364.
3. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011; 365: 1567-1575.
4. Jithoo A, Enright PL, Burney P, et al. Case-finding options for COPD: results from the Burden of Obstructive Lung Disease study. Eur Respir J 2013; 41: 548-555.
5. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study. Eur Respir J 2012; 40: 830-836.
6. Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history. Eur Respir J 2011; 38: 553-560.
7. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210-223.
8. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
9. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179-191.
10. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
11. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
12. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
13. Rabe KF, Cooper CB. Global Initiative on Obstructive Lung Disease revised: what constitutes a guideline? Am J Respir Crit Care Med 2013; 187: 1035-1036.
14. Agusti A, Hurd S, Jones P, et al. FAQs about the GOLD 2011 assessment proposal of COPD: A comparative analysis of four different cohorts. Eur Respir J 2013; 42: 1391-1401.
15. Johannessen A, Nilsen RM, Storebo M, et al. Comparison of 2011 and 2007 global initiative for chronic obstructive lung disease guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med 2013; 188: 51-59.
16. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013; 42: 636-646.
17. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: A prospective cohort study. Lancet Respir Med 2013; 1: 43-50.
18. Soriano JB, Alfageme I, Almagro P, et al. Distribution and prognostic validity of the new global initiative for chronic obstructive lung disease grading classification. Chest 2013; 143: 694-702.
19. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: A study of the general population. Am J Respir Crit Care Med 2012; 186: 975-981.
20. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
21. Jones PW, Adamek L, Nadeau G, et al. Comparisons of health status scores with MRC grades in COPD: implications for the new GOLD 2011 classification. Eur Respir J 2013; 42: 647-654.
22. O'Reilly J, Jones MM, Parnham J, et al. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010; 340: c3134.